GLPwatch
In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
Ann Intern Med · 2022
Last updated 2026-05-28In a 72-week study of 2,539 adults with obesity but without diabetes, participants who took tirzepatide alongside lifestyle changes lost an average of 15% of their body weight, compared to 3% for those who received a placebo and lifestyle changes alone.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2022 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.05 |
| NIH percentile | 5 |
| Molecules | tirzepatide |
| Conditions studied | Obesity |
Abstract
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387:205-16. 35658024.
Verbatim abstract via PubMed 36191308 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.